Teva Pharma Industries Ltd ADR (TEVA)

Nov 13, 2026

Teva Pharmaceutical Industries EVP Richard Daniell sold 20,003 shares of the company's stock for over $856,000, reducing his direct stake by 26.4%. This follows an earlier sale of 25,000 shares. The company recently surpassed quarterly earnings and revenue expectations, and analysts maintain a generally positive outlook with an average target price of $48.15.

Nov 12, 2026

Teva Pharmaceutical Industries Ltd. CEO Richard Francis announced an increase in the company's revenue target for innovative medicines by 2030, raising it to $6-7 billion. Francis highlighted Teva's transformation from a generics-focused company into a biopharma entity, with branded drugs expected to account for over 25% of total revenue by 2030, up from 9% in 2022. Despite past challenges, Francis expressed confidence that Teva will continue to prove its capabilities to investors and analysts.

Nov 11, 2026

Teva Pharmaceutical Industries Ltd. has increased its 2030 revenue target for innovative medicines to $6 billion to $7 billion, up from a previous goal of over $5 billion. This announcement was made during its first R&D Day, where the company also outlined other ambitious targets including innovative gross margins above 75% and mid-single-digit total revenue growth from 2026. Teva anticipates launching one new innovative medicine annually through 2030, with its late-stage pipeline having a combined peak sales potential exceeding $10 billion.

Nov 10, 2026

Private Management Group Inc. reduced its stake in Teva Pharmaceutical Industries by 20.8% in the third quarter, selling over 100,000 shares. Despite this, Teva exceeded quarterly earnings expectations and received a "Moderate Buy" consensus rating from analysts with an average price target of $47.23. Insiders, however, have sold approximately $16.6 million in shares over the past 90 days.

Nov 9, 2026

Teva Pharmaceutical Industries and Samsung Bioepis have expanded their biosimilars partnership through a new licensing and commercialisation agreement for two FDA-approved immunology biosimilars in the US. Teva will gain US commercialisation rights to ETICOVO and infliximab-abda, strengthening its immunology portfolio and aligning with its "Pivot to Growth" strategy. Samsung Bioepis will continue to be responsible for regulatory oversight and manufacturing of these treatments, which reference Enbrel and Remicade respectively.

Nov 6, 2026

Teva Pharmaceutical Industries Ltd (TEVA) reported Q3 2026 revenue of $4.4 billion, a 2% year-over-year decrease, yet saw significant growth in its innovative portfolio, with products like AUSTEDO, UZEDY, and AJOVY showing strong performance. The company raised its full-year 2026 guidance for revenue, operating income, Adjusted EBITDA, EPS, and free cash flow, and improved its gross margin. Despite a decline in generics revenue and some pipeline setbacks, Teva is strategically positioned for growth, particularly in biosimilars, and is actively managing potential impacts from IRA implementation and litigation risks.

Nov 3, 2026

Teva Pharmaceutical Industries (TEVA) reported strong Q3 2026 sales of US$4.4 billion, surpassing some analyst expectations, driven by key branded drugs and a new biosimilars agreement with Samsung Bioepis. This performance has led management to raise its 2026 outlook for these products, with analysts projecting a significant increase in profits by 2029. While the company faces risks like choppy profits and an R&D setback, the focus remains on its branded portfolio and biosimilar partnership to drive future growth.

Nov 3, 2026

Teva Pharmaceutical, a leading global generic drug manufacturer, is expected to achieve long-term outperformance driven by its focus on innovation and strategic pipeline additions. Despite facing price erosion in small-molecule oral tablets, the company is prioritizing other business segments for future growth. Recent developments, including the Weltruza approval and additions to its neurology portfolio, underscore Teva's commitment to deepening its expertise and pursuing growth opportunities through deals.

Nov 3, 2026

Teva Pharmaceutical Industries has shown strong performance, returning about 378.8% over the past three years. Despite this, a Discounted Cash Flow (DCF) model suggests that Teva's intrinsic value, especially considering recent neuroscience pipeline expansions, remains substantially above its current share price of $40.70, indicating it may still be undervalued based on its future cash flow generation. The article also mentions a community narrative that views the stock as 14% undervalued due to a robust launch queue of new assets through at least 2030.

Nov 3, 2026

Teva Pharmaceutical Industries has signed an agreement with Samsung Bioepis to commercialize two FDA-approved biosimilars, ETICOVO and infliximab-abda, in the United States. This deal will expand Teva's immunology portfolio, targeting inflammatory and autoimmune conditions. Teva will make an upfront payment and additional payments tied to launches and sales milestones, expecting the transaction to close by the end of 2026.

Nov 3, 2026

Teva Pharmaceutical Industries Ltd. and Samsung Bioepis Co., Ltd. announced a license and commercialization agreement for two FDA-approved immunology biosimilars: infliximab-abda (biosimilar to Remicade®) and ETICOVO® (etanercept-ykro, biosimilar to Enbrel®). Teva will gain U.S. commercialization rights, with etanercept-ykro at closing and infliximab-abda in Q3 2027, while Samsung Bioepis will manage regulatory oversight and manufacturing. This agreement expands Teva's immunology portfolio and aims to increase patient access to high-quality medicines for chronic inflammatory conditions.

Nov 2, 2026

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) stock is trading lower after its U.S. affiliate decided to discontinue its Phase 2 TOPAS-MSA study for emrusolmin. An interim futility analysis indicated a low probability of the study achieving its primary efficacy goal, though no safety concerns were identified. This decision only impacts the TOPAS-MSA trial and not the broader emrusolmin clinical program.

Nov 2, 2026

HC Wainwright has initiated coverage of Teva Pharmaceutical Industries (NYSE:TEVA) with a "buy" rating and a $52 price target, indicating a 23.6% potential upside. The company has a consensus "Moderate Buy" rating from analysts with an average target price of $46.54, though insiders have sold approximately $14.6 million in stock recently. Teva Pharmaceutical Industries is a global pharmaceutical company specializing in generic and specialty medicines.

Nov 2, 2026

Teva Pharmaceuticals announced it is discontinuing its mid-stage study for the experimental oral drug emrusolmin, designed to treat multiple system atrophy. The decision was based on an independent data monitoring committee's recommendation, indicating a low probability of the study meeting its primary goal if continued. Despite the setback, Teva stated no safety concerns were identified and remains committed to analyzing the data and the broader emrusolmin program.